← Back to Clinical Trials
RecruitingPhase 2NCT06848348
Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain
Trial Parameters
ConditionChemotherapy Induced Neuropathic Pain
SponsorDogwood Therapeutics Inc.
Study TypeINTERVENTIONAL
PhasePhase 2
Enrollment200
SexALL
Min Age18 Years
Max AgeN/A
Start Date2025-02-21
Completion2026-07
Interventions
HalneuronPlacebo
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
A randomized study to determine safety and efficacy of single subcutaneous (SC) administration of HAL treatment in patients with CINP.
Eligibility Criteria
Inclusion Criteria: * Male or female patients aged ≥18 years. * Neuropathic pain has been present and is attributed to platinum and/or taxane chemotherapy. * Patient has received a cancer chemotherapy regimen that included taxanes and/or platinum and has no active or discernible disease progression. Exclusion Criteria: * Current neuropathic pain with symptoms similar to CINP but attributed to causes other than platinum or taxane chemotherapy. * Patients who have received HAL at any time prior to screening.